{"id":"https://openalex.org/W7208788141","doi":"https://doi.org/10.64898/2026.09.01.26361919","title":"No Overall Survival Benefit with Adding Chemotherapy to Immunotherapy in PD-L1 TPS \u2265 50% NSCLC: An Agent-Stratified Reassessment","display_name":"No Overall Survival Benefit with Adding Chemotherapy to Immunotherapy in PD-L1 TPS \u2265 50% NSCLC: An Agent-Stratified Reassessment","publication_year":2026,"publication_date":"2026-09-03","ids":{"openalex":"https://openalex.org/W7208788141","doi":"https://doi.org/10.64898/2026.09.01.26361919"},"language":"en","primary_location":{"id":"doi:10.64898/2026.09.01.26361919","doi":"https://doi.org/10.64898/2026.09.01.26361919","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.09.01.26361919","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/09/03/2026.09.01.26361919.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},"volume":null,"type":"preprint","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.medrxiv.org/content/medrxiv/early/2026/09/03/2026.09.01.26361919.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015217744","display_name":"Fujun Han","orcid":"https://orcid.org/0000-0003-2926-5398","observed_orcids":["https://orcid.org/0000-0003-2926-5398","https://orcid.org/0000-0002-7226-1301"]},"institutions":[{"id":"https://openalex.org/I4210125137","display_name":"First Hospital of Jilin University","ror":"https://ror.org/034haf133","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210125137"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Fujun Han","raw_affiliation_strings":["Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China","institution_ids":["https://openalex.org/I4210125137"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5150020383","display_name":"Jinwen Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125137","display_name":"First Hospital of Jilin University","ror":"https://ror.org/034haf133","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210125137"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jinwen Wang","raw_affiliation_strings":["Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China","institution_ids":["https://openalex.org/I4210125137"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5150003526","display_name":"Songchen Shi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125137","display_name":"First Hospital of Jilin University","ror":"https://ror.org/034haf133","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210125137"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Songchen Shi","raw_affiliation_strings":["Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China","institution_ids":["https://openalex.org/I4210125137"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5140481624","display_name":"Meile Jin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125137","display_name":"First Hospital of Jilin University","ror":"https://ror.org/034haf133","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210125137"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Meile Jin","raw_affiliation_strings":["Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China","institution_ids":["https://openalex.org/I4210125137"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019325315","display_name":"Chunhui Ren","orcid":"https://orcid.org/0000-0002-1795-6530","observed_orcids":["https://orcid.org/0000-0002-1795-6530"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chunhui Ren","raw_affiliation_strings":["Department of Oncology, Tonghua People\u2019s Hospital, Tonghua, Jilin, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Tonghua People\u2019s Hospital, Tonghua, Jilin, China","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5015217744"],"corresponding_institution_ids":["https://openalex.org/I4210125137"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chemoimmunotherapy","display_name":"chemoimmunotherapy","score":0.9729999899864197},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8820000290870667},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8709999918937683},{"id":"https://openalex.org/keywords/pd-l1-tumor-proportion-score","display_name":"PD-L1 tumor proportion score","score":0.906000018119812},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7480000257492065},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":1.0},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.4950000047683716},{"id":"https://openalex.org/keywords/treatment-effect-generalizability","display_name":"treatment effect generalizability","score":0.4350000023841858}],"concepts":[{"id":"https://openalex.org/C2780790343","wikidata":"https://www.wikidata.org/wiki/Q5090610","display_name":"Chemoimmunotherapy","level":4,"score":0.9894999861717224},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.819100022315979},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7426000237464905},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.673799991607666},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6733999848365784},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5770000219345093},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5662000179290771},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.4771000146865845},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.46369999647140503},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.41760000586509705},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.38850000500679016},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.3714999854564667},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.35670000314712524},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.34529998898506165},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.32899999618530273},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.30559998750686646},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.28870001435279846},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.28369998931884766},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.27970001101493835},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.2515000104904175}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.64898/2026.09.01.26361919","doi":"https://doi.org/10.64898/2026.09.01.26361919","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.09.01.26361919","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/09/03/2026.09.01.26361919.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.64898/2026.09.01.26361919","doi":"https://doi.org/10.64898/2026.09.01.26361919","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.09.01.26361919","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/09/03/2026.09.01.26361919.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320310121","display_name":"Natural Science Foundation of Jilin Province","ror":null},{"id":"https://openalex.org/F4320322300","display_name":"Jilin University","ror":"https://ror.org/00js3aw79"},{"id":"https://openalex.org/F4320327282","display_name":"Department of Science and Technology of Jilin Province","ror":"https://ror.org/049x38272"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7208788141.pdf","grobid_xml":"https://content.openalex.org/works/W7208788141.grobid-xml"},"referenced_works_count":29,"referenced_works":["https://openalex.org/W1600041372","https://openalex.org/W2005947177","https://openalex.org/W2527905628","https://openalex.org/W2635951006","https://openalex.org/W2796582438","https://openalex.org/W2892640821","https://openalex.org/W2925446385","https://openalex.org/W2946386783","https://openalex.org/W2976744492","https://openalex.org/W3017322331","https://openalex.org/W3047859155","https://openalex.org/W3091399767","https://openalex.org/W3110814768","https://openalex.org/W3111665711","https://openalex.org/W3118615836","https://openalex.org/W3129022890","https://openalex.org/W3144903047","https://openalex.org/W3164993995","https://openalex.org/W3165007730","https://openalex.org/W3183409909","https://openalex.org/W4200204256","https://openalex.org/W4205569586","https://openalex.org/W4293237625","https://openalex.org/W4303488453","https://openalex.org/W4308179948","https://openalex.org/W4386997634","https://openalex.org/W4401199548","https://openalex.org/W4404135209","https://openalex.org/W7163574930"],"related_works":["https://openalex.org/W3097223462","https://openalex.org/W3032088728","https://openalex.org/W7163574930","https://openalex.org/W4404056601","https://openalex.org/W7140107301","https://openalex.org/W3120298769","https://openalex.org/W7162647417","https://openalex.org/W7212059895","https://openalex.org/W2947835494","https://openalex.org/W4400351223"],"abstract_inverted_index":{"Abstract":[0],"IMPORTANCE":[1],"A":[2],"recent":[3],"meta-analysis":[4,81,138,321],"showed":[5],"that":[6],"chemoimmunotherapy":[7,120,147,248],"was":[8,139,158,179,209,279],"associated":[9],"with":[10,16,309,331],"improved":[11],"overall":[12],"survival":[13,54,98],"(OS)":[14],"compared":[15],"immune":[17],"checkpoint":[18],"inhibitor":[19],"(ICI)":[20],"monotherapy":[21,61,150,300,333],"for":[22,94,146,221,234,249,287,343],"programmed":[23],"death-ligand":[24],"1":[25,165],"(PD-L1)":[26],"tumor":[27],"proportion":[28],"score":[29],"(TPS)":[30],"\u2265":[31,312],"50%":[32,313],"advanced":[33,314],"non-small-cell":[34],"lung":[35],"cancer":[36],"(NSCLC).":[37],"However,":[38],"whether":[39],"this":[40],"benefit":[41,55,317],"reflects":[42],"chemotherapy":[43,58,152,297],"effect":[44],"or":[45,305],"ICI":[46,60,117,149,299,332],"heterogeneity":[47],"remains":[48],"unclear.":[49],"OBJECTIVE":[50],"To":[51],"reassess":[52],"the":[53,79,106,293,319,341],"of":[56,274],"adding":[57,296],"to":[59,66,272,298],"using":[62],"agent-stratified":[63],"comparisons":[64,115,125,199,238],"anchored":[65],"chemotherapy.":[67],"DATA":[68,87],"SOURCES":[69],"The":[70,168,316],"24":[71],"phase":[72],"3":[73],"randomized":[74],"clinical":[75],"trials":[76,273],"included":[77],"in":[78,105,118,127,172,307,318,346],"original":[80,107,320],"(search":[82],"date,":[83],"August":[84],"3,":[85],"2025).":[86],"EXTRACTION":[88],"AND":[89,189,290],"SYNTHESIS":[90],"Hazard":[91],"ratios":[92],"(HRs)":[93],"OS":[95,193,222,250,304],"and":[96,121,123,148,155,194,223,258,339],"progression-free":[97],"(PFS)":[99],"were":[100,112,153,170,192],"extracted":[101],"from":[102,181],"each":[103],"trial":[104],"meta-analysis.":[108],"Two":[109],"analytic":[110],"frameworks":[111],"used:":[113],"within-agent":[114,133,198,294],"(same":[116],"both":[119],"monotherapy)":[122],"across-agent":[124,176,237],"(ICI":[126],"one":[128],"treatment":[129,185],"strategy":[130],"only).":[131],"For":[132,175],"comparisons,":[134,177,295],"a":[135,268,335],"two-stage":[136],"random-effects":[137],"conducted.":[140],"In":[141,197,236,267,292],"stage":[142,173],"1,":[143],"ICI-specific":[144],"HRs":[145,183],"versus":[151],"pooled":[154,171,182,207,277],"their":[156],"ratio":[157],"calculated":[159],"(RHR":[160],"=":[161,205,215,219,229,232,244,256,285],"HRchemoimmuno/HRmono;":[162],"RHR":[163,178,208,246,278],"<":[164,265],"favors":[166],"chemoimmunotherapy).":[167],"RHRs":[169],"2.":[174],"derived":[180],"by":[184,324],"strategy.":[186],"MAIN":[187],"OUTCOMES":[188],"MEASURES":[190],"Endpoints":[191],"PFS.":[195,235],"RESULTS":[196],"(4":[200],"ICIs;":[201,240],"13":[202],"trials;":[203,242],"N":[204,243],"3252),":[206],"0.94":[210],"(95%":[211,225,281],"CI,":[212,226,253,262,282],"0.78\u20131.13;":[213],"P":[214,228,255,264,284],".48;":[216],"I":[217],"\u00b2":[218],"0.0%)":[220,233],"0.85":[224],"0.68\u20131.06;":[227],".14;":[230],"I\u00b2":[231],"(7":[239],"11":[241],"2231),":[245],"favored":[247],"(0.68;":[251],"95%":[252,261],"0.50\u20130.92;":[254],".01)":[257],"PFS":[259,306],"(0.46;":[260],"0.37\u20130.58;":[263],".001).":[266],"sensitivity":[269],"analysis":[270],"restricted":[271],"NCCN-recommended":[275],"regimens,":[276],"1.02":[280],"0.81\u20131.28;":[283],".87)":[286],"OS.":[288],"CONCLUSIONS":[289],"RELEVANCE":[291],"did":[301],"not":[302],"improve":[303],"patients":[308],"PD-L1":[310],"TPS":[311],"NSCLC.":[315],"appears":[322],"driven":[323],"across-ICI":[325],"heterogeneity.":[326],"These":[327],"findings":[328],"are":[329],"consistent":[330],"as":[334],"standard":[336],"first-line":[337],"option":[338],"underscore":[340],"need":[342],"agent-level":[344],"stratification":[345],"across-trial":[347],"comparisons.":[348]},"counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2026-09-05T00:00:00"}